Paul Mampilly Shares Insight into the Announcement by Amazon Entering the Pharmacy Industry

For people who are looking for a mentor in the financial world, look no further than Paul Mampilly. He is one of the smartest investors in the United States and has helped many financial institutions make millions of dollars over the years. One of the primary aims of Paul Mampilly has always been to help the firms he is working for to make profits, and no matter which institution he has worked for, Paul has always given results. Some of the major financial corporations that Paul Mampilly has worked for include ING, Deutsche Bank, and Royal Bank of Scotland. After leaving the banking sector, Paul Mampilly joined the Kinetics Asset Management, which is one of the top hedge funding corporations today. Read more articles by Paul Mampilly at Banyan Hill.

When Paul Mampilly joined Kinetics Asset Management, the net worth of the corporation was around $6 Billion, but under the leadership of Paul, it crossed $25 Billion. Even the Barron’s named the fund of Kinetics Asset Management as one of the best in the country. Paul Mampilly currently holds the position of Chief Editor at a respected finance based publishing house by the name of Banyan Hill Publishing. Paul Mampilly also owns and runs a newsletter named Profits Unlimited through which it aims to help people identify the stocks that they should purchase for short and long-term investment. Paul Mampilly wants to educate people about how they should invest their money and where they should invest their money as it is how the common population would be able to contribute to the society and grow at the same time. Read more about Paul Mampilly at Talk Markets.

Paul Mampilly provides information about the recent developments in different industries that can impact the prices of stocks. One such example is that of Amazon that is believed to be entering the pharmacy market. Amazon disrupts the business of its competitors in any industry that it enters. Recently they announced that they would be entering the pharmacy market and it would allow them to provide pharmaceutical products directly to the consumers cutting the middlemen. It will help bring down the cost of the products. The news has already led to a decrease in the stock prices of many pharmacies, and the effect is expected to continue. Thus, Paul Mampilly asks his readers to refrain from investing in pharmacies for the coming months till the total effect of Amazon is not fully understood. Till then, it is best to invest in companies that are developing 3D printing technology.

Check: http://releasefact.com/2018/03/paul-mampilly-advises-subscribers-invest-precision-medicine/